Alerts will be sent to your verified email
Verify Email
AUROPHARMA
|
Aurobindo Pharma
|
Abbott India
|
Alkem Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
API Sector
|
|||
|
US DMF Filings
|
297.0 . | n/a | n/a |
|
Europe DMF Filings
|
2077.0 . | n/a | n/a |
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
853.0 . | n/a | 178.0 . |
|
Number of ANDA's Approved By USFDA
|
704.0 . | n/a | 152.0 . |
|
R&D as a % of Total Sales
|
5.6 % | 0.02 % | 4.3 % |
|
Financials
|
|||
|
5 yr Average ROE
|
13.97 % | 28.3 % | 17.42 % |
|
5yr average Equity Multiplier
|
1.51 | 1.45 | 1.42 |
|
5yr Average Asset Turnover Ratio
|
0.71 | 1.15 | 0.89 |
|
5yr Avg Net Profit Margin
|
12.77 % | 17.01 % | 13.9 % |
|
Price to Book
|
2.37 | 18.12 | 5.43 |
|
P/E
|
20.92 | 47.82 | 28.98 |
|
5yr Avg Cash Conversion Cycle
|
-49.62 Days | -49.8 Days | -31.98 Days |
|
Inventory Days
|
59.48 Days | 47.03 Days | 55.32 Days |
|
Days Receivable
|
28.34 Days | 19.26 Days | 41.28 Days |
|
Days Payable
|
115.71 Days | 108.53 Days | 114.28 Days |
|
5yr Average Interest Coverage Ratio
|
43.78 | 83.18 | 24.2 |
|
5yr Avg ROCE
|
16.69 % | 36.46 % | 22.93 % |
|
5yr Avg Operating Profit Margin
|
19.28 % | 21.84 % | 18.1 % |
|
5 yr average Debt to Equity
|
0.21 | 0.0 | 0.21 |
|
5yr CAGR Net Profit
|
2.21 % | 15.17 % | 9.76 % |
|
5yr Average Return on Assets
|
9.18 % | 19.59 % | 12.26 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.82 % | 74.99 % | 55.13 % |
|
Share Pledged by Promoters
|
16.92 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.01 % | 0.0 | -2.0 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
8.12 % | 3.42 % | 7.45 % |
|
Aurobindo Pharma
|
Abbott India
|
Alkem Laboratories
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|